Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Apr 13;101(6):1282–1286. doi: 10.1016/j.kint.2022.04.009

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 International Society of Nephrology. Published by Elsevier Inc. All rights reserved.

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

PMC Copyright notice

Poor anti–receptor binding domain (RBD) antibody and neutralization responses to the Omicron variant before and after the third dose of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mRNA vaccine in kidney transplant recipients (KTRs). (a,b) Anti–SARS-CoV-2 RBD IgG antibody OD 450 values to wild-type (WT), Delta (B.1.617.2), and Omicron (B.1.1.529) variants of SARS-CoV-2 before and after the third vaccine dose in KTRs (n = 51; a) and in prepandemic healthy controls (HCs; n = 5) and prepandemic kidney transplant control patients (KCs; n = 15), measured by enzyme-linked immunosorbent assay (b). (c,d) Percentage of neutralization to WT, Delta, and Omicron variants of SARS-CoV-2 before and after the third vaccine dose in KTRs (n = 51; c) and in prepandemic HCs (n = 5) and KCs (n = 15), measured by surrogate virus neutralization test (d). Horizontal lines indicate positivity threshold for assay. (e) Proportion of KTRs with a positive neutralization response before and after the third vaccine dose in KTRs. (a,c) Statistic by Friedman test with Dunn correction for multiple comparisons. (e) Statistic by χ² test.